Sail Biomedicines Advances In Vivo eRNA CAR-T Data

CAMBRIDGE, Mass., April 27, 2026

Sail Biomedicines announced it will present new preclinical data supporting its In Vivo eRNA™ CAR-T platform at the ASGCT 2026 Annual Meeting and TIDES USA 2026, highlighting a next-generation approach to autoimmune disease treatment. The findings emphasize the platform’s dose efficiency, targeted delivery, and ability to achieve deep B-cell depletion, positioning it as a potentially transformative therapy in immune-mediated disorders.

Innovative In Vivo CAR-T Strategy for Autoimmune Diseases

Sail Biomedicines’ lead program leverages a novel In Vivo eRNA-TNP (targeted nanoparticle) CAR-T approach, which enables direct programming of T cells داخل the body without the need for ex vivo cell manipulation. This strategy combines circular eRNA constructs with proprietary targeted nanoparticles, designed to deliver therapeutic payloads specifically to CD4 and CD8 T cells. By enabling controlled and sustained CAR expression, the platform aims to create a precise therapeutic window that can achieve a functional immune reset in autoimmune diseases..

Preclinical data presented from nonhuman primate studies and other models demonstrate that the therapy achieves deep and sustained B-cell depletion across blood and key lymphoid tissues, including bone marrow and lymph nodes. This level of systemic immune targeting is critical for addressing autoimmune conditions, where pathogenic B cells drive disease progression. The ability to eliminate these cells effectively while maintaining safety highlights the platform’s strong translational potential.

Dose Efficiency and Targeted Delivery Advantages

One of the most compelling aspects of Sail’s platform is its low-dose potency and targeted delivery capability. The targeted nanoparticle system ensures that eRNA constructs are delivered with high specificity to immune cells, reducing off-target effects and enhancing therapeutic precision. This results in a favorable dose-efficiency profile, which could translate into improved safety, reduced toxicity, and better patient tolerability compared to traditional CAR-T therapies.

Additionally, the platform’s ability to engage both CD4 and CD8 T cell populations enables a more comprehensive immune response, enhancing the durability and depth of therapeutic effects. By avoiding the complexities of cell harvesting and manufacturing associated with conventional CAR-T approaches, Sail’s In Vivo system offers a scalable and accessible alternative, potentially expanding patient access to advanced cell therapies.

Advancing Programmable RNA Medicines to the Clinic

Sail Biomedicines is at the forefront of programmable RNA medicine innovation, combining AI-driven design with advanced delivery technologies to create next-generation therapeutics. Its eRNA™ platform, based on circular RNA constructs, provides enhanced stability and sustained protein expression, making it particularly suitable for complex therapeutic applications such as CAR-T.

The company’s participation in major scientific forums underscores its commitment to accelerating clinical translation of its lead candidate and broader pipeline. By demonstrating robust preclinical efficacy and a differentiated product profile, Sail is advancing toward clinical development with a strong foundation of scientific validation.

The implications of this technology extend beyond autoimmune diseases, with potential applications in oncology, immunology, and other complex disorders. As the field of cell and gene therapy continues to evolve, Sail’s In Vivo CAR-T approach represents a paradigm shift, moving from personalized ex vivo treatments to off-the-shelf, in-body programmable therapies.

With increasing demand for safer, more effective, and scalable immune therapies, Sail Biomedicines’ platform could redefine how CAR-T treatments are developed and delivered. The data presented at ASGCT and TIDES USA 2026 reinforce the company’s position as a leader in RNA-based therapeutic innovation, driving the next wave of precision medicine and curative treatment strategies.

Source: Sail Biomedicines press release